Non-Small Cell Lung Cancer (NSCLC) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2032

Non-Small Cell Lung Cancer (NSCLC) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2032

Report Format: PDF+Excel | Report ID: SR112023A6561
Buy Now

1 Preface

2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Non-Small Cell Lung Cancer (NSCLC) - Introduction
4.1 Overview
4.2 Epidemiology (2017-2021) and Forecast (2022-2032)
4.3 Market Overview (2017-2021) and Forecast (2022-2032)
4.4 Competitive Intelligence

5 Non-Small Cell Lung Cancer (NSCLC) - Disease Overview
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment

6 Patient Journey

7 Non-Small Cell Lung Cancer (NSCLC) - Epidemiology and Patient Population
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2017-2021)
7.2.2 Epidemiology Forecast (2022-2032)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2017-2021)
7.3.2 Epidemiology Forecast (2022-2032)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2017-2021)
7.4.2 Epidemiology Forecast (2022-2032)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2017-2021)
7.5.2 Epidemiology Forecast (2022-2032)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2017-2021)
7.6.2 Epidemiology Forecast (2022-2032)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2017-2021)
7.7.2 Epidemiology Forecast (2022-2032)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2017-2021)
7.8.2 Epidemiology Forecast (2022-2032)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2017-2021)
7.9.2 Epidemiology Forecast (2022-2032)

8 Non-Small Cell Lung Cancer (NSCLC) - Treatment Algorithm, Guidelines, and Medical Practices
8.1 Non-Small Cell Lung Cancer (NSCLC) Guidelines, Management and Treatment
8.2 Non-Small Cell Lung Cancer (NSCLC) Treatment Algorithm

9 Non-Small Cell Lung Cancer (NSCLC) - Unmet Needs

10 Non-Small Cell Lung Cancer (NSCLC) - Key Endpoints of Treatment

11 Non-Small Cell Lung Cancer (NSCLC) - Marketed Products
11.1 List of Non-Small Cell Lung Cancer (NSCLC) Marketed Drugs Across the Top 7 Markets
11.1.1    Rozlytrek (Entrectinib) - Hoffmann-La Roche
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2    Imfinzi (Durvalumab) - AstraZeneca
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3    Opdivo (Nivolumab) - Bristol-Myers Squibb
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4    Keytruda (Pembrolizumab) - Merck
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
11.1.5    Vizimpro (Dacomitinib) - Pfizer
11.1.5.1 Drug Overview
11.1.5.2 Mechanism of Action
11.1.5.3 Regulatory Status
11.1.5.4 Clinical Trial Results
11.1.5.5 Sales Across Major Markets

Kindly note that the above only represents a partial list of marketed drugs and the complete list has been provided in the report

12 Non-Small Cell Lung Cancer (NSCLC) - Pipeline Drugs
12.1 List of Non-Small Cell Lung Cancer (NSCLC) Pipeline Drugs Across the Top 7 Markets
12.1.1 EGF816 (Nazartinib) - Novartis Pharmaceuticals
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 Telisotuzumab Vedotin - AbbVie
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 SAR408701 (Tusamitamab Ravtansine) - Sanofi
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 ACZ885 (Canakinumab) - Novartis
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 BAVENCIO (Avelumab) - Merck/Pfizer
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status

Kindly note that the above only represents a partial list of pipeline drugs and the complete list has been provided in the report

13. Non-Small Cell Lung Cancer (NSCLC) - Attribute Analysis of Key Marketed and Pipeline Drugs

14 Non-Small Cell Lung Cancer (NSCLC) - Market Scenario
14.1 Market Scenario - Key Insights
14.2 Market Scenario - Top 7 Markets
14.2.1    Non-Small Cell Lung Cancer (NSCLC) - Market Size
14.2.1.1 Market Size (2017-2021)
14.2.1.2 Market Forecast (2022-2032)
14.2.2    Non-Small Cell Lung Cancer (NSCLC) - Market Size by Therapies
14.2.2.1 Market Size by Therapies (2017-2021)
14.2.2.2 Market Forecast by Therapies (2022-2032
14.3 Market Scenario - United States
14.3.1    Non-Small Cell Lung Cancer (NSCLC) - Market Size
14.3.1.1 Market Size (2017-2021)
14.3.1.2 Market Forecast (2022-2032)
14.3.2    Non-Small Cell Lung Cancer (NSCLC) - Market Size by Therapies
14.3.2.1 Market Size by Therapies (2017-2021)
14.3.2.2 Market Forecast by Therapies (2022-2032)
14.3.3    Non-Small Cell Lung Cancer (NSCLC) - Access and Reimbursement Overview
14.4 Market Scenario - Germany
14.4.1    Non-Small Cell Lung Cancer (NSCLC) - Market Size
14.4.1.1 Market Size (2017-2021)
14.4.1.2 Market Forecast (2022-2032)
14.4.2    Non-Small Cell Lung Cancer (NSCLC) - Market Size by Therapies
14.4.2.1 Market Size by Therapies (2017-2021)
14.4.2.2 Market Forecast by Therapies (2022-2032)
14.4.3    Non-Small Cell Lung Cancer (NSCLC) - Access and Reimbursement Overview
14.5 Market Scenario - France
14.5.1    Non-Small Cell Lung Cancer (NSCLC) - Market Size
14.5.1.1 Market Size (2017-2021)
14.5.1.2 Market Forecast (2022-2032)
14.5.2    Non-Small Cell Lung Cancer (NSCLC) - Market Size by Therapies
14.5.2.1 Market Size by Therapies (2017-2021)
14.5.2.2 Market Forecast by Therapies (2022-2032)
14.5.3    Non-Small Cell Lung Cancer (NSCLC) - Access and Reimbursement Overview
14.6 Market Scenario - United Kingdom
14.6.1    Non-Small Cell Lung Cancer (NSCLC) - Market Size
14.6.1.1 Market Size (2017-2021)
14.6.1.2 Market Forecast (2022-2032)
14.6.2    Non-Small Cell Lung Cancer (NSCLC) - Market Size by Therapies
14.6.2.1 Market Size by Therapies (2017-2021)
14.6.2.2 Market Forecast by Therapies (2022-2032)
14.6.3    Non-Small Cell Lung Cancer (NSCLC) - Access and Reimbursement Overview
14.7 Market Scenario - Italy
14.7.1    Non-Small Cell Lung Cancer (NSCLC) - Market Size
14.7.1.1 Market Size (2017-2021)
14.7.1.2 Market Forecast (2022-2032)
14.7.2    Non-Small Cell Lung Cancer (NSCLC) - Market Size by Therapies
14.7.2.1 Market Size by Therapies (2017-2021)
14.7.2.2 Market Forecast by Therapies (2022-2032)
14.7.3    Non-Small Cell Lung Cancer (NSCLC) - Access and Reimbursement Overview
14.8 Market Scenario - Spain
14.8.1    Non-Small Cell Lung Cancer (NSCLC) - Market Size
14.8.1.1 Market Size (2017-2021)
14.8.1.2 Market Forecast (2022-2032)
14.8.2    Non-Small Cell Lung Cancer (NSCLC) - Market Size by Therapies
14.8.2.1 Market Size by Therapies (2017-2021)
14.8.2.2 Market Forecast by Therapies (2022-2032)
14.8.3    Non-Small Cell Lung Cancer (NSCLC) - Access and Reimbursement Overview
14.9   Market Scenario - Japan
14.9.1    Non-Small Cell Lung Cancer (NSCLC)  - Market Size
14.9.1.1 Market Size (2017-2021)
14.9.1.2 Market Forecast (2022-2032)
14.9.2    Non-Small Cell Lung Cancer (NSCLC) - Market Size by Therapies
14.9.2.1 Market Size by Therapies (2017-2021)
14.9.2.2 Market Forecast by Therapies (2022-2032)
14.9.3    Non-Small Cell Lung Cancer (NSCLC) - Access and Reimbursement Overview

15 Non-Small Cell Lung Cancer (NSCLC) - Recent Events and Inputs From Key Opinion Leaders

16 Non-Small Cell Lung Cancer (NSCLC) Market - SWOT Analysis
16.1 Strengths
16.2 Weaknesses
16.3 Opportunities
16.4 Threats     

17 Appendix

Non-Small Cell Lung Cancer (NSCLC) Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2032
Select Licence Type



Benefits of Customization

Personalize This Research

Triangulate with your Data

Get Data as per your Format and Definition

Gain a Deeper Dive into a Specific Application, Geography, Customer or Competitor

Any level of Personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Clients Testimonial

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Bayer AH

It was indeed a great experience to work with IMARC on the assignment on Aqua market. The team had done a fantastic job in terms of what was expected, what was assured and what was the result… the report gave us many insights and market know how which allowed us to work on our strength and define exact strategies…

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More